246513-41-7

Basic information

• Product Name: 3-(3-Carbomethoxy-2-bromoanilino)-cyclohex-2-en-1-one
• Synonyms: 3-(3-Carbomethoxy-2-bromoanilino)-cyclohex-2-en-1-one
• CAS NO: 246513-41-7
• Molecular Weight: 324.174
• Mol File: 246513-41-7.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-(3-Carbomethoxy-2-bromoanilino)-cyclohex-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-Carbomethoxy-2-bromoanilino)-cyclohex-2-en-1-one(246513-41-7)
• EPA Substance Registry System: 3-(3-Carbomethoxy-2-bromoanilino)-cyclohex-2-en-1-one(246513-41-7)

Safety Data

• Hazardous Substances Data: 246513-41-7(Hazardous Substances Data)

Upstream product

• 504-02-9 1,3-cylohexanedione 
• 106896-48-4 methyl 2-bromo-3-aminobenzoate 

Downstream Products

• 1446260-98-5 2,2,10-trimethyl-2,3,5,10-tetrahydro-[1,2]diazepino[3,4,5,6-def]carbazol-6(1H)-one 
• 246513-43-9 9-[(phenyl)methyl]-5-carbomethoxy-1,2-dihydrocarbazol-4(3H)-one 

Relevant articles and documents

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development

Poly (ADP-ribose) polymerase (PARP) plays a significant role in DNA repair responses; therefore, this enzyme is targeted by PARP inhibitors in cancer therapy. Here we have developed a number of fused tetra- or pentacyclic dihydrodiazepinoindolone derivatives with excellent PARP enzymatic and cellular PARylation inhibition activities. These efforts led to the identification of pamiparib (BGB-290, 139), which displays excellent PARP-1 and PARP-2 inhibition with IC50 of 1.3 and 0.9 nM, respectively. In a cellular PARylation assay, this compound inhibits PARP activity with IC50 = 0.2 nM. Cocrystal of pamiparib shows similar binding sites with PARP with other PARP inhibitors, but pamiparib is not a P-gp substrate and shows excellent drug metabolism and pharmacokinetics (DMPK) properties with significant brain penetration (17-19%, mice). The compound is currently being investigated in phase III clinical trials as a maintenance therapy in platinum-sensitive ovarian cancer and gastric cancer.

Diaza tropolium ion carbazole IDO inhibitor and application thereof

The invention belongs to the field of chemical medicine and particularly relates to a diaza tropolium ion carbazole IDO inhibitor or the pharmaceutically acceptable salt thereof, pharmaceutical compositions containing the compounds, and application of the

FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.